IQ-AI Subsidiary Launches Hopeful Brain Tumor Treatment Program
Company Announcements

IQ-AI Subsidiary Launches Hopeful Brain Tumor Treatment Program

IQ-AI Limited (GB:IQAI) has released an update.

IQ-AI Limited’s subsidiary, Imaging Biometrics, has launched an Expanded Access Program for gallium maltolate, a treatment for recurrent brain tumors, after receiving FDA approval. The program offers hope to patients with glioblastoma who are unable to participate in clinical trials by providing access to this investigational therapy. CEO Trevor Brown emphasizes the potential benefit to patients given the positive safety results from ongoing clinical studies.

For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskIQ-AI Limited Eyes Revenue Growth and New Partnerships
TipRanks UK Auto-Generated NewsdeskBraveheart Investment Group Acquires Major Stake in IQ-AI Limited
TipRanks UK Auto-Generated NewsdeskIQ-AI Limited Reports Progress and New Milestones
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App